Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug tested to soothe stubborn celiac symptoms

NCT ID NCT04424927

Summary

This study tested an investigational drug called PRV-015 in adults with celiac disease who still experienced symptoms like pain, bloating, and diarrhea despite following a strict gluten-free diet. The goal was to see if the drug could safely reduce these persistent symptoms. Participants were randomly assigned to receive either one of three doses of the drug or a placebo, in addition to continuing their diet.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CELIAC DISEASE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Clinical Site

    Los Angeles, California, 90036, United States

  • Clinical Site

    Ventura, California, 93003, United States

  • Clinical Site

    Denver, Colorado, 80209, United States

  • Clinical Site

    Leesburg, Florida, 34748, United States

  • Clinical Site

    Tampa, Florida, 33613, United States

  • Clinical Site

    Winter Park, Florida, 32789, United States

  • Clinical Site

    Chicago, Illinois, 60637, United States

  • Clinical Site

    Boston, Massachusetts, 02111, United States

  • Clinical Site

    Chesterfield, Michigan, 48047, United States

  • Clinical Site

    Rochester, Minnesota, 55905, United States

  • Clinical Site

    Morristown, New Jersey, 07960, United States

  • Clinical Site

    New Windsor, New York, 12553, United States

  • Clinical Site

    Raleigh, North Carolina, 27607, United States

  • Clinical Site

    Philadelphia, Pennsylvania, 19104, United States

  • Clinical Site

    Uniontown, Pennsylvania, 14401, United States

  • Clinical Site

    Warwick, Rhode Island, 02886, United States

  • Clinical Site

    Nashville, Tennessee, 37212, United States

  • Clinical Site

    Garland, Texas, 75044, United States

  • Clinical Site

    West Jordan, Utah, 84088, United States

  • Clinical Site

    Bellevue, Washington, 98004, United States

  • Clinical Site

    Tacoma, Washington, 98405, United States

  • Clinical Site

    Hamilton, Ontario, L8S4K1, Canada

  • Clinical Site

    Amsterdam, 1105 AZ, Netherlands

  • Clinical Site

    Seville, Andalusia, 41013, Spain

  • Clinical Site

    León, Castille and León, 24071, Spain

  • Clinical Site

    Madrid, 28034, Spain

  • Clinical Site

    Madrid, 28041, Spain

  • Clinical Site

    Madrid, 28222, Spain

  • Clinical Trial Site

    Northbrook, Illinois, 60062, United States

  • Clinical Trial Site

    Chevy Chase, Maryland, 20815, United States

  • Clinical Trial Site

    Brooklyn, New York, 11235, United States

  • Clinical Trial Site

    New York, New York, 10032, United States

  • Clinical Trial Site

    Dublin, Ohio, 43016, United States

  • Clinical Trial Site

    North Charleston, South Carolina, 29405, United States

  • Clinical Trial Site

    Cedar Park, Texas, 78613, United States

  • Clinical Trial Site

    Terrassa, Catalonia, 082211, Spain

  • Clinical Trial Site

    Girona, 17007, Spain

  • Clinical Trial Site

    Lleida, 25196, Spain

Conditions

Explore the condition pages connected to this study.